Patents by Inventor Allan James Saul

Allan James Saul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240293524
    Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.
    Type: Application
    Filed: March 28, 2024
    Publication date: September 5, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Renzo ALFINI, Roberta Di Benedetto, Francesca Micoli, Allan James Saul
  • Patent number: 12036285
    Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: July 16, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Renzo Alfini, Francesca Micoli, Allan James Saul
  • Patent number: 12005109
    Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: June 11, 2024
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Renzo Alfini, Roberta Di Benedetto, Francesca Micoli, Allan James Saul
  • Patent number: 11986518
    Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: May 21, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Christiane Gerke, Laura Bartle Martin, Allan James Saul
  • Publication number: 20230263877
    Abstract: A Shigella flexneri O-antigen of a first serotype or subserotype are provided for use in raising an immune response against one or more Shigella flexneri O-antigen of a different serotype or subserotype, together with associated binding moieties, pharmaceutical compositions, kits, uses or methods.
    Type: Application
    Filed: October 15, 2020
    Publication date: August 24, 2023
    Inventors: Francesco Citiulo, Laura Bartle Martin, Allan James Saul
  • Publication number: 20230137821
    Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.
    Type: Application
    Filed: November 23, 2017
    Publication date: May 4, 2023
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Renzo ALFINI, Francesca MICOLI, Allan James SAUL
  • Publication number: 20230137914
    Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.
    Type: Application
    Filed: November 23, 2017
    Publication date: May 4, 2023
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Roberta DI BENEDETTO, Francesca MICOLI, Allan James SAUL
  • Publication number: 20220008529
    Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 13, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Renzo ALFINI, Roberta DI BENEDETTO, Francesca MICOLI, Allan James SAUL
  • Publication number: 20200384096
    Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.
    Type: Application
    Filed: August 5, 2020
    Publication date: December 10, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Christiane GERKE, Laura Bartle MARTIN, Allan James SAUL
  • Patent number: 10683370
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 16, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Allan James Saul, Francesca Micoli
  • Publication number: 20180334515
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 22, 2018
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Allan James SAUL, Francesca MICOLI
  • Patent number: 10113009
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 30, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Allan James Saul, Francesca Micoli
  • Patent number: 10098947
    Abstract: The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 16, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Calman Alexander MacLennan, Laura Bartle Martin, Francesca Micoli, Allan James Saul
  • Publication number: 20180169206
    Abstract: This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Christiane GERKE, Laura Bartle MARTIN, Allan James SAUL
  • Publication number: 20160297895
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Application
    Filed: May 9, 2016
    Publication date: October 13, 2016
    Inventors: Allan James SAUL, Francesca MICOLI
  • Publication number: 20160263213
    Abstract: The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 15, 2016
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Calman Alexander MACLENNAN, Laura Bartle MARTIN, Francesca MICOLI, Allan James SAUL
  • Patent number: 9358284
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 7, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Allan James Saul, Francesca Micoli
  • Publication number: 20140329998
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Allan James Saul, Francesca Micoli
  • Publication number: 20130017219
    Abstract: A two stage size filtration process is used to purify immunogenic bacterial vesicles. A first step separates the vesicles from intact bacteria based on their different sizes, with the smaller vesicles passing into the filtrate (permeate). A second step then uses a finer filter to remove smaller contaminants, with the vesicles remaining in the retentate. This two stage process is extremely simple to operate but has been shown to give vesicles of high purity.
    Type: Application
    Filed: September 28, 2010
    Publication date: January 17, 2013
    Applicant: NOVARTIS VACCINES INSTITUTE FOR GLOBAL HEALTH SRL
    Inventors: Vito Di Cioccio, Anna Maria Colucci, Allan James Saul
  • Patent number: 6174528
    Abstract: The present invention relates generally to chimeric peptides comprising one or more protective epitopes in a conformation enabling inmunological interactivity and to vaccine compositions comprising same. The present invention is particularly directed to a chimeric peptide capable of inducing protecting antibodies against Group A streptococci.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: January 16, 2001
    Assignees: Counsel of the Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research of Royal Melbourne Hospital, Biotech Australia PTY Limited, CSL Limited
    Inventors: Juan Anton Cooper, Wendy Anne Relf, Michael Francis Good, Allan James Saul